Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;40(8):2026-2033.
doi: 10.1002/nau.24790. Epub 2021 Sep 9.

Efficacy of fesoterodine fumarate (8 mg) in neurogenic detrusor overactivity due to spinal cord lesion or multiple sclerosis: A prospective study

Charalampos Konstantinidis  1 , Michael Samarinas  2 , Moira Tzitzika  1 , Zisis Kratiras  1 , Georgios Panagiotakopoulos  3 , Konstantinos Giannitsas  4 , Anastasios Athanasopoulos  4
Affiliations

Efficacy of fesoterodine fumarate (8 mg) in neurogenic detrusor overactivity due to spinal cord lesion or multiple sclerosis: A prospective study

Charalampos Konstantinidis et al. Neurourol Urodyn. 2021 Nov.

Abstract

Aims: Antimuscarinic drugs are the first-line choice in the treatment of patients with neurogenic Detrusor Overactivity (nDO). Fesoterodine fumarate is the newest antimuscarinic drug. Limited data are published about the use of fesoterodine fumarate in patients suffering from neurogenic lower urinary tract dysfunction. Our study aims to determine the efficacy of fesoterodine fumarate on patients with nDO due to spinal cord lesion or multiple sclerosis (MS).

Methods: This is an open-label prospective interventional study. Eligible patients were 18-80 years old with SCL or MS and nDO confirmed by a urodynamic study (UDS). At baseline, patients underwent a UDS to confirm nDO. Quality of life (QoL) was assessed by the Short-Form (SF) Qualiveen questionnaire. Patients received fesoterodine 8 mg/day for 3 months and were re-evaluated with UDS and SF-Qualiveen. The primary endpoint was the confirmation of the maximum detrusor pressure (Pdetmax ) reduction after treatment. Secondary endpoints were: evaluation of maximum bladder capacity and compliance and QoL effect. Statistical analysis included Wilcoxon-test using SPSSv26.

Results: One hundred and twenty-four patients completed the study. Ninety-five of them (76.6%) had SCL, while 29 (23.4%) had MS. Pdetmax , maximum bladder capacity, and compliance had significant reduction after treatment (p < .001) in the whole group and each subgroup. SF-Qualiveen revealed a significant increase in QoL in each group (p < .001).

Conclusions: Fesoterodine fumarate (8 mg) is an efficacious drag in patients with SCL and MS, as it significantly decreases the detrusor pressure, increases the bladder capacity and compliance, and improves the QoL.

Keywords: fesoterodine fumarate; multiple sclerosis (MS); neurogenic bladder; neurogenic detrusor overactivity (nDO); spinal cord lesion (SCL).

PubMed Disclaimer

References

REFERENCES

    1. Gajewski JB, Schurch B, Hamid R, et al. An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourol Urodyn. 2018;37(3):1152-1161. https://doi.org/10.1002/nau.23397
    1. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl):S580-S590.
    1. Tang DH, Colayco D, Piercy J, Patel V, Globe D, Chancellor MB. Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity. BMC Neurol. 2014;14:74. https://doi.org/10.1186/1471-2377-14-74
    1. Thompson HJ, Mauk KL. Nursing management of the patient with multiple sclerosis: AANN ARN, and IOMSN Clinical Practice Guideline Series. 2011. http://iomsn.org/wp-content/uploads/2016/07/AANN-ARN-IOMSN-MSGuideline_F...
    1. Blok B, Castro-Diaz D, Del Popolo J, et al. EAU Guidelines on Neuro-Urology 2020. EAU Guidelines Office, Arnhem. The Netherlands. http://www.uroweb.org/guideline/neuro-urology/

MeSH terms

LinkOut - more resources